4-aminobenzoic acid has been researched along with Brain Neoplasms in 3 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study assessed the efficacy of RG7388 as a single-agent and in combination with chemotherapies currently used to treat neuroblastoma in a panel of neuroblastoma cell lines." | 5.42 | Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. ( Chen, L; Lunec, J; Middleton, SA; Newell, DR; Nichols, GL; Rousseau, RF; Tweddle, DA, 2015) |
| "Glioblastoma (GBM) is a malignant brain tumor with a poor long-term prognosis due to recurrence from highly resistant GBM cancer stem cells (CSCs), for which the current standard of treatment with temozolomide (TMZ) alone will unlikely produce a viable cure." | 4.02 | Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. ( Ayyagari, P; Das, SK; Pollok, KE; Shannon, HE; Smiley, SB; Vannier, MW; Veronesi, MC; Yun, Y, 2021) |
| " This study assessed the efficacy of RG7388 as a single-agent and in combination with chemotherapies currently used to treat neuroblastoma in a panel of neuroblastoma cell lines." | 1.42 | Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. ( Chen, L; Lunec, J; Middleton, SA; Newell, DR; Nichols, GL; Rousseau, RF; Tweddle, DA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Smiley, SB | 1 |
| Yun, Y | 1 |
| Ayyagari, P | 1 |
| Shannon, HE | 1 |
| Pollok, KE | 1 |
| Vannier, MW | 1 |
| Das, SK | 1 |
| Veronesi, MC | 1 |
| Chen, L | 1 |
| Rousseau, RF | 1 |
| Middleton, SA | 1 |
| Nichols, GL | 1 |
| Newell, DR | 1 |
| Lunec, J | 1 |
| Tweddle, DA | 1 |
| Kogias, E | 1 |
| Osterberg, N | 1 |
| Baumer, B | 1 |
| Psarras, N | 1 |
| Koentges, C | 1 |
| Papazoglou, A | 1 |
| Saavedra, JE | 1 |
| Keefer, LK | 1 |
| Weyerbrock, A | 1 |
3 other studies available for 4-aminobenzoic acid and Brain Neoplasms
| Article | Year |
|---|---|
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Topics: AC133 Antigen; Animals; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug De | 2021 |
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Drug Screening As | 2015 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain N | 2012 |